Metabolic Syndrome: A Comprehensive Textbook (Hardcover, 2016)

Foreword Preface Part 1: Epidemiology (i) Overview: Definition, prevalence in adults and children, morbidity, mortality (ii) Obesity and metabolic syndrome in North America (iii) Obesity and metabolic syndrome in Europe (iv) Obesity and metabolic syndrome in Latin America (v) Obesity and metabolic syndrome in Sub-Saharan Africa (v) Obesity and metabolic syndrome in the Middle East (vi) Obesity and metabolic syndrome in Asia (vii) Obesity and metabolic syndrome in Australia, New Zealand and Polynesia Part 2: Genetics (i) Genetics of obesity (ii) Genetics of type 2 diabetes (iii) Genetics of lipid disorders (iv) Genetics of atherosclerosis Part 3: Environmental factors (i) Gestational factors, obesity and metabolic syndrome (ii) Influence of early postnatal environment on obesity and metabolic syndrome (breast feeding, weaning, family environment) (iii) Diet, obesity and metabolic syndrome (calories, macronutrients, high fructose corn syrup, micronutrients) (iv) Exercise and non-exercise physical activity, obesity and metabolic syndrome (v) Influence of housing, transportation, TV and electronic media on obesity and metabolic syndrome (vi) Social and community networks, obesity and metabolic syndrome Part 4: Pathophysiology (i) Energy homeostasis (ii) Metabolism of carbohydrate, proteins and lipids (iii) CNS regulation of feeding and energy homeostasis (iv) Adipose tissue (structure, WAT and BAT, adipokines, fuel metabolism) (v) Gut pathophysiology (motor, exocrine, endocrine) (vi) Endocrine pancreas (alpha, beta , other cells, insulin defects in obesity) (vii) Insulin resistance and metabolic syndrome (viii) Gut microbiome, obesity and metabolism (ix) Atherogenic dyslipidemia (x) Inflammation, endothelial dysfunction, and atherogenesis (xi) Skeletal muscle, myokines and metabolism (xii) Sleep, circadian rhythms and metabolism Part 5: Diseases associated with obesity (i) Type 2 diabetes (natural history, pathogenesis, assessment of insulin resistance and beta cell dysfunction, treatment) (ii) Cardiovascular morbidity (CAD; stroke) (iii) Non-alcoholic fatty liver disease (iv) Obstructive sleep apnea, obesity and metabolic syndrome (v) Obesity, GERD, Barrett's esophagus (vii) Connecting metabolic syndrome and cancer (viii) Sarcopenic obesity (ix) Obesity, PCOS and infertility (x) Endocrinopathies associated with obesity (insulin, thyroid, glucocorticoids, growth hormone) (xi) Obesity, metabolic syndrome and dementia Part 6: Management (i) Assessment of obesity and cardiometabolic risk (body composition, laboratory investigation, imaging, novel biomarkers) (ii) Diet, exercise, behavior therapy (iii) Pharmacotherapy (iv) Bariatric surgery (v) Childhood interventions (school -based and other programs) (vi) Community, national and global interventions_